Key result
This review discusses the evolving role and optimal use of glycoprotein IIb/IIIa inhibitors in the contemporary treatment of non-ST-segment elevation acute coronary syndrome and PCI.
The role of glycoprotein IIb/IIIa inhibitors in NSTE-ACS and PCI requires ongoing re-evaluation in the context of new concomitant and alternative medications.
Re-evaluation of GP IIb/IIIa inhibitors needed in NSTE-ACS and PCI; leaves open optimal use with newer agents.
Results from clinical trials of glycoprotein IIb/IIIa(GPIIb/IIIa) inhibitors during the past decade have established their current role in the treatment of non-ST-segment elevation acute coronary syndrome and in percutaneous coronary interventions. However, there are still unanswered questions on optimal use of GPIIb/IIIa inhibitors. Moreover, as new concomitant or alternative medications become available, the role of GPIIb/IIIa inhibitors must be reconsidered. This review discusses, in the light of clinical trials recently presented, what we know, what we are learning, and what we still need to learn.
No takes yet. Share an insight, caveat, or question.
Tricoci et al. (2006) conducted a review in Acute Coronary Syndrome. Glycoprotein IIb/IIIa inhibitors was evaluated. This review discusses the evolving role and optimal use of glycoprotein IIb/IIIa inhibitors in the contemporary treatment of non-ST-segment elevation acute coronary syndrome and PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: